Goldman Sachs Keeps Their Sell Rating on Humana (HUM)
Goldman Sachs analyst Scott Fidel maintained a Sell rating on Humana yesterday and set a price target of $158.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fidel covers the Healthcare sector, focusing on stocks such as CVS Health, Humana, and Molina Healthcare. According to TipRanks, Fidel has an average return of 9.1% and a 63.78% success rate on recommended stocks.
In addition to Goldman Sachs, Humana also received a Sell from TipRanks – Anthropic’s Anthropic Medical – Healthcare Plans in a report issued yesterday. However, today, Wells Fargo maintained a Hold rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $32.52 billion and a GAAP net loss of $796 million. In comparison, last year the company earned a revenue of $29.21 billion and had a GAAP net loss of $693 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Humana: Uncertain Margin Recovery and Star Rating Headwinds Drive Neutral ‘Hold’ Stance
- Humana price target lowered to $206 from $290 at Wells Fargo
- Humana price target lowered to $200 from $285 at Truist
- Humana price target lowered to $173 from $260 at TD Cowen
- Humana price target lowered to $180 from $231 at Deutsche Bank
